The Trump administration has approved a $2.8 billion sale of munitions to Israel, highlighting challenges in the Israeli military’s capacity to independently sustain its stockpiles of heavy ordinance. The package, which includes tens of thousands of bombs and one-ton bunker-busting warheads, follows a request from Israel amid ongoing regional tensions.

The munitions involved resemble those produced by Israeli defense contractor Elbit Systems, which expanded its production lines during the Gaza conflict under the direction of Israel’s Defense Ministry. However, domestic manufacturing is reportedly insufficient to meet the military’s consumption rates, particularly during wartime when as many as 1,200 air-to-ground munitions may be deployed daily.

A source familiar with the issue indicated that Israel’s local production cannot keep pace with operational demands, in part due to the complexity of acquiring the necessary raw materials for mass production. This supply gap has prompted Washington’s intervention to approve the sale, which some observers view as politically motivated. The Trump administration seeks to demonstrate unconditional support by agreeing to Israel’s requests without imposing restrictions.

At the same time, concerns have increasingly surfaced among American arms manufacturers over the reputational risks linked to their involvement. A senior Israeli official involved in procurement recounted a recent exchange with a U.S. defense contractor expressing unease about the public optics of munitions sales, especially in light of civilian casualties associated with Israeli operations in Gaza. “They understand our needs, but it just doesn’t look good,” the official said, reflecting a growing discomfort within the industry about the ongoing conflict.

Some critical components of the munitions, including guidance systems intended to minimize civilian harm during combat, have faced delays in U.S. approval. Yet, the recent authorization of the $2.8 billion package has no immediate operational impact. Finalization depends on subsequent approvals from the U.S. Congress and Israel’s ministerial procurement committee, and Israel has yet to allocate budgetary resources for new orders under this deal.

While some reports have suggested that U.S. taxpayers would bear the cost, the current American aid agreement between the two countries—valid through 2029—already dedicates funding to existing Israeli defense procurements, primarily for air force equipment. Consequently, if Congress approves the deal and Israel proceeds with purchases, the financial burden is expected to fall on Israel’s own defense budget, denominated in shekels.

This arrangement is not unprecedented; according to recent information, Israel has spent an additional $2 billion to $3 billion annually from its defense budget on American weapons and ammunition over the past three years, supplementing provided U.S. aid.

Currently, Israel faces budget shortfalls that prevent it from funding additional heavy munitions or fulfilling prior U.S.-approved purchases, including Apache attack helicopters, Sikorsky CH-53K helicopters, and aerial refueling tankers, as well as Joint Direct Attack Munition (JDAM) guidance kits.

A defense source noted that the Israeli government faces significant financial constraints and political uncertainty ahead of upcoming elections, which are creating delays in defining long-term military funding strategies. “Everyone’s waiting for the Israeli election to see who’ll negotiate on our behalf,” the source said, emphasizing the need for clear fiscal planning and more realistic expectations following statements made by Prime Minister Benjamin Netanyahu and President Donald Trump, which have heightened concern within Israel’s defense establishment.